Rate My Professor Rimma Goldberg

Goldberg’s research focuses on developing novel cell-based therapies for IBD, particularly regulatory T cell (Treg) therapies to suppress inflammation in Crohn’s disease. During her PhD, she pioneered a Treg-based treatment now in Phase 1 clinical trials in the United Kingdom. Since returning to Australia, she has built collaborative networks to translate this therapy locally, supported by the School of Clinical Sciences Career Development Fellowship and a Crohn’s and Colitis Australia Research Prize. She leads grants including antigen-specific Treg therapy for ulcerative colitis, gastrointestinal-restricted ALK5 inhibitors for intestinal fibrosis, and studies on thiopurine metabolites and pharmacotherapies in pregnancy-related IBD. Her publications feature in high-impact journals such as Gut, Gastroenterology, and Nature Reviews Gastroenterology. Key papers include “Vedolizumab and Ustekinumab Levels in Pregnant Women With Inflammatory Bowel Disease and Infants Exposed In Utero” (Clinical Gastroenterology and Hepatology, 2025), “Thiopurine Metabolite Shunting in Late Pregnancy Increases the Risk of Intrahepatic Cholestasis of Pregnancy in Women with Inflammatory Bowel Disease” (Journal of Crohn’s and Colitis, 2024), “Colonic cytomegalovirus DNA detection by polymerase chain reaction does not influence outcomes in inflammatory bowel disease” (Internal Medicine Journal, 2024), “Thrombocytosis and Transaminitis in Infants Born to Women With Inflammatory Bowel Disease” (Inflammatory Bowel Diseases, 2024), and “Thiopurine metabolite testing in inflammatory bowel disease” (Therapeutic Advances in Gastroenterology, 2016). Awards include the British Society of Gastroenterology Best Scientific Abstract Award and the Society of Mucosal Immunology Rising Stars in Mucosal Immunology award.